CRC Research Update — July 31, 2026
Today's colorectal cancer research highlights
kras
A collection of 33 issues
CRC Research Update — July 30, 2026
Today's colorectal cancer research highlights
KRAS mutations drive immune evasion through RNA modifications
Skip to content
The CRC Digest
◇ RESEARCH
KRAS mutations drive immune evasion through RNA modifications
Preclinical research found that KRAS mutations remodel RNA m6A modifications to increase CD73 expression, promoting immune evasion in colorectal cancer. (Cancer Research)
This content is informational only and does not constitute medical advice.
Always consult
KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy
Skip to content
The CRC Digest
◇ RESEARCH
KRAS G12D Inhibitor Reshapes Immune Landscape, Enhances NK Cell Therapy
Preclinical research shows that KRAS G12D inhibition with MRTX1133 remodels the tumor immune environment by reducing immunosuppressive cells and facilitating infiltration of natural killer and CD8+ T cells, reversing systemic immunosuppression and restoring
CRC Research Update — July 25, 2026
Today's colorectal cancer research highlights
CRC Research Update — July 16, 2026
Today's colorectal cancer research highlights
Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination
Skip to content
The CRC Digest
Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination
Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84
CRC Research Update — July 15, 2026
Today's colorectal cancer research highlights
CRC Research Update — July 14, 2026
Today's colorectal cancer research highlights
CRC Research Update — July 13, 2026
Today's colorectal cancer research highlights